Possible Answers
1. Typically, patients have hundreds of small fine granules within their platelets that appear red-purple to royal purple against the gray-pink cytoplasmic background. 1 Normal platelets with their granules can be seen in Image 1.
Platelets contain alpha and dense granules that assist in coagulation and activation, among other functions ( Table   2 ).
2, 3 The alpha granules are more numerous and are visible via light microscopy, whereas the dense granules are much fewer in number and are only visible via electron microscopy. 4 The patient had peripheral blood smears made from blood collected in an EDTA tube and then others smears made from blood collected in a sodium citrate tube. An unexpected finding was that platelets from the blood in the EDTA tube were difficult to visualize and appeared to lack granules, whereas the platelets in the blood from the sodium citrate tube had normal-appearing granules. 4, 5, 6 A hypogranular platelet from a smear of the blood of the patient collected in an EDTA tube can be seen in Image 2; platelets with normal granulation are seen in the peripheral smear of blood from the sodium citrate-containing tube in Image 3.
2. The differential diagnosis includes myelodysplastic syndrome (MDS), gray platelet syndrome (GPS), and pseudogray platelet syndrome (PGPS). 
Image 1
Unremarkable ethylenediaminetetraaceticacid (EDTA) peripheral blood smear from a healthy patient, containing platelets and neutrophils with normal granulation (original magnification, × 400X). Arrows identify normal platelets. A second possible diagnosis is the rare, congenital GPS, also known as platelet alpha-granule deficiency syndrome. This is primarily inherited as an autosomal recessive disorder involving the NBEAL2 gene on chromosome 3p, which encodes a protein with a BEACH domain; this is important for vesicular trafficking and for the development of alpha granules. [8] [9] [10] GPS is characterized by agranular-appearing platelets that are vacuolated and decreased in number. Patients have increased bleeding tendencies, which generally are mild to moderate but occasionally can be severe, including postsurgical bleeding and intracranial hemorrhage. GPS is often associated with myelofibrosis of the bone marrow and perhaps with pulmonary fibrosis as well. Splenomegaly may also be present. In GPS, only the alpha
Image 2
Ethylenediaminetetraacetic acid (EDTA) peripheral blood specimens from our patient, which demonstrate markedly hypogranular platelets (also called gray or ghost platelets) identified by arrow (original magnification, × 400X). The neutrophil is also hypogranular and appears atypical or activated.
Image 3
Citrated peripheral blood smear from our patient, showing normal granulation of the platelets (original magnification, × 400X). The neutrophils, however, remain hypogranular. Arrow identifies a granular platelet.
granules of the platelets are affected, whereas the dense granules are not. 11, 12 Platelets will appear gray in blood and bone marrow from any type of anticoagulant or preservative because the alpha granules are defective. The proteins in plasma, such as albumin and immumnoglobulins, that are engulfed via endocytosis (Table 2 ) are severely deficient within the gray platelets. 2, 9, 13 Proteins synthesized by the megakaryocytes, such as beta-thromboglobulin, are decreased within the alpha granules but may be elevated in the bone marrow or plasma; this perhaps reflects defective targeting and packaging of synthesized proteins, resulting in their subsequent loss into their surrounding areas. The release of increased amounts of plateletderived growth factor, normally stored within the platelet granules, into the bone-marrow environment is thought to be a major contributor to bone-marrow fibrosis in patients with GPS.
11, 14 Drouin et al 14 indicated that neutrophils may also be affected because a decrease in the number of secondary granules is noted in the neutrophils of patients found to have GPS.
PGPS is an extremely rare in vitro phenomenon or artifact. In contrast to GPS, the platelets in PGPS contain apparently normal alpha granules that degranulate upon collection in EDTA tubes (in some patients, the dense granules also degranulate) but not in sodium citrate, heparin, acid citrate dextrose (ACD) or other anticoagulants or preservatives. 4, 6 It is unknown exactly what causes this anomaly, which has only been reported in a few patients. In case studies such as that by Toyota et al, 6 the patients with PGPS did not exhibit lifelong bleeding tendencies, unlike patients with GPS. Cockbill et al 5 discussed how the cause of the EDTA-induced hypogranulation of the platelets is different from the EDTA-dependent antibodies that cause pseudothrombocytopenia through platelet clumping and/ or platelet satellitism; however, there are differing interpretations of these phenomena within the literature. 4, 5 Unlike GPS or EDTA-dependent antibody platelet agglutination and platelet satellitism, thrombocytopenia and pseudothrombocytopenia are not present in PGPS; also, the platelet counts will be the same in EDTA and sodium citrate blood samples. Therefore, the EDTA peripheral blood samples may be run through impedance automated hematology analyzers (and at least 1 optical analyzer) with accurate platelet counts. The mean platelet volume (MPV), however, may be inaccurate due to platelet swelling or cell lysis. Manual platelet counts are generally unnecessary for confirming the accuracy of the count because platelet clumping is not present. Crossover studies using the EDTA-anticoagulated plasma of a patient with PGPS mixed with normal patients' platelets demonstrate degranulation of normal patients' platelets, just as the PGPS platelets degranulate in EDTA. Therefore, some factor in the plasma of the patient with PGPS appears to be responsible for the degranulation-possibly an antibody to a hidden (crypt) platelet site exposed through activation with EDTA, which is similar to but different from the antibody that occurs in EDTA-induced platelet agglutination. 4 3. The peripheral blood smear should always be reviewed first to make sure that platelet clumping and platelet satellitism are not present. Review of the other cell lines is useful to look for dysplastic features that favor MDS or agranular neutrophils, which might be observed in MDS or GPS. The neutrophils in our patient were hypogranular and had a slightly atypical or activated appearance (Image 2). This may indicate that the factor(s) that affects the degranulation of the platelets could be the same or similar factors as those that interact with neutrophils to cause degranulation. However, the patient's neutrophils from the citrated blood (Image 3) were also hypogranular and atypical in appearance. Abnormal neutrophils were not noted in previous PGPS case studies, making this patient's neutrophil abnormalities unlikely to be related to PGPS. Some polychromatophillic erythrocytes were present; otherwise, the patient's red blood cells (RBCs) were unremarkable. Of note, the technologist who first reviewed the EDTA peripheral blood smear stained the same slide a second time because of the gray-appearing platelets and lack of staining of the platelet granules, without any improvement in the appearance of the granules.
Because our patient had long-term unexplained thrombocytopenia, examination of the bone marrow was important to rule out MDS, which was done based on the lack of dysplastic features. The normal chromosome analysis and absence of infection or malignant neoplasms affecting the bone marrow also provided useful information. Because the megakaryocytes in our patient's bone marrow had normal granulation, as observed in non-EDTA-anticoagulated specimens, GPS was also unlikely. The results of plateletspecific antibody testing were negative in our patient at this time.
Serum levels of vitamin B 12 and plasma levels of betathromboglobulin are consistently elevated in patients with GPS. 9, 13 Our patient had a normal vitamin B 12 level; betathromboglobulin was not performed.
Bleeding times are increased typically in GPS and may be increased in MDS; however, many facilities such as ours no longer perform bleeding times. Platelet aggregation stud-ies may show abnormal aggregation in MDS (nonspecific pattern) or GPS (abnormal aggregation with thrombin and collagen agonists).
Electron microscopy searching for alpha platelet granules in non-EDTA specimens would definitively diagnose GPS versus PGPS. 9 Further research is needed to determine the identity of the plasma factor(s) present or altered in patients with PGPS that result(s) in the hypogranular platelets observed in our patient's EDTA-anticoagulated specimen. Flow cytometric studies for platelet and neutrophil markers can detect activation of these cells. Testing using flow cytometry and electron microscopy was discussed with our patient's hematologist but was not performed because the patient had no previous personal or family history of abnormal bleeding. Platelets and neutrophils interact for inflammatory defense mechanisms via factors such as P-selectin, ß 2 and ß 3 integrins, CD11b/CD18, CD4/CD61. Platelets also produce cytokines to assist in the inflammatory process by recruiting neutrophils and interacting with endothelial cells and monocytes.
3 P-selectin, ß 2 , and ß 3 integrins, and inflammatory cytokines or unique platelet activators could be further studied for abnormalities in these patients. 4 . On review, we believed the appearance of the hypogranular platelets on the patient's EDTA peripheral blood smear and the normally granulated platelets on the sodium citrate smear to be consistent with PGPS, especially in light of the patient's negative history of previous abnormal bleeding. Other testing ruled out MDS and GPS or made those conditions unlikely, further strengthening the case for PGPS (the results of additional testing performed on the patient's serum are presented in Table 3 ). Because PGPS does not cause thrombocytopenia and the bone-marrow biopsy results were fairly unremarkable, the hematologist suspected that the patient's longstanding thrombocytopenia was medication-related and advised stopping or changing, if possible, some of the medications taken by the patient that are known to cause thrombocytopenia, such as Lasix and Zocor. Alternate theories suggested for the thrombocytopenia were shearing of the platelets from the aneurysm itself and/or early-onset MDS with very slow progression, or possibly interaction of the patient's weakly positive antiphospholipid antibody with the phospholipids in the platelet membranes to cause mild thrombocytopenia. 11,12 The goals of treatment for MDS involve improving symptoms, quality of life, and overall survival, while decreasing progression to acute leukemia. Based on performance status and prognostic factors, treatment ranges from supportive care with blood products and growth factors to hypomethylating agents, cytidine analogs, the thalidomide derivative lenalidomide, and stem-cell transplants. 
Patient Follow Up
The patient's abdominal aortic aneurysm (AAA) was repaired in July 2011; he tolerated the procedure well. Due to his thrombocytopenia, he received 2 units of platelets; his estimated blood loss was 200 mL. The patient has followed up with his primary-care physician regarding his thrombocytopenia every 3 to 6 months, which he will continue to do as long as his condition remains stable. He has been instructed to return to the hematologist if his platelet count decreases significantly or if other hematologic issues arise. His platelet count, to date, has remained in the 60-to 80 × 10 9 /L range during the past 2 years since his AAA repair surgery. LM 
